CanSino Biologics Inc.: COVID-19 trials

The registry lists 11 COVID-19 studies with CanSino Biologics Inc. as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 VaccineWithdrawnNCT05442684Phase 3
• Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and OlderCompletedNCT05373485Phase 1
• Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and OlderCompletedNCT05373472Phase 2
• A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and AdolescentsTerminatedNCT05169008Phase 3
• Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)WithdrawnNCT05124561Phase 3
• A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.CompletedNCT04916886Not applicable
• Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for InhalationCompletedNCT04840992Phase 1/2
• A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)CompletedNCT04566770Phase 2
• Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and AboveCompletedNCT04526990Phase 3
• Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in CanadaStatus unknownNCT04398147Phase 1/2
• Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy AdultsCompletedNCT04313127Phase 1